About US
Contact us
-
Jury: Boy didn't prove J&J drug caused his breast growthJohnson & Johnson ($JNJ) won a split decision in Philadelphia court Friday, in the latestRisperdallawsuit to go to trial. A jury decided that J&J did fail to warn doctors that the antipsychoti2015/3/24
-
Hedge fund patent challenges are growing by the numbers, and drugmakers aren't happyGenerics makers aren't the only ones filing challenges to pharma patents anymore. Hedge funds are doing it, too, and it's got drugmakers on edge. The funds, taking advantage of rulesCongresscreated t2015/3/23
-
Biogen Alzheimer's drug reignites excitementThe success of Biogen Idec's ($BIIB) closely watched antibody targeting beta amyloid proteins inAlzheimer'sdisease is again bringing some excitement to a category that has defeated earlier enthusiasm2015/3/23
-
Big Pharma's market cap stars of 2014: Lilly, AbbVie, AstraZenecaWho can resist a numbers match-up? Not us, obviously. Even better when the winners are a bit unexpected. Today, it's market cap, courtesy ofEvaluatePharmaand its annual state of the industry report.2015/3/20
-
Sanofi's Shantha prepared to deliver 37M doses of long-delayed pediatric vaccineSanofi ($SNY) faced a long delay before its Indian affiliate,Shantha Biotechnics, finally came through with the launch of its low-cost pediatric pentavalent vaccine, Shan5. But now that it has, it say2015/3/20
-
The top 15 pharma companies by 2014 revenueThe names at the very top of our yearly list of biggest pharma companies are no surprise. Johnson & Johnson ($JNJ), Novartis ($NVS), Roche ($RHHBY) and Pfizer ($PFE) have headed up the rankings fo2015/3/19
-
England's Cancer Drugs Fund changes its tune, holds onto Novartis' AfinitorIn the face of a backlash from drugmakers, England's Cancer Drugs Fund (CDF) is backtracking in its decision to remove certain treatments from its list of covered drugs. It has agreed to keep Novartis2015/3/19
-
China's drug approval backlog swells as it gets nearly 9,000 applications in 2014Western drugmakers have complained about how long it can take to get a drug approved for sale in China. Here is why,FiercePharmaAsiareports, citingReuters:Chinahad a backlog of more than 18,500 drugs2015/3/18
-
Hep C meds cost-effective, but affordable? With new 46% discounts, maybeWhenhepatitis Cdrugmakers started wooing payers with discounts, the cost cuts made the difference between an overwhelming burden and cost-effective spending. So say two new studies looking at the cost2015/3/18
-
Cost watchdogs back Novartis' Xolair for big new market in chronic hivesEngland's cost-effectiveness watchdogs have changed their mind on Xolair. The National Institute for Health and Care Excellence (NICE)decided to back the Novartis ($NVS) asthma drug as a treatment for2015/3/17